ETNB
89bio, Inc.
$14.84
+0.00
(+0.00%)
Mkt Cap
2.20B
Volume
38,511,212
52W Range
4.16-15.06
Sector
Healthcare
Beta
1.26
EPS (TTM)
-3.61
P/E Ratio
-2.23
Revenue (TTM)
21,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (367.08M) | (142.19M) | (102.03M) | (90.12M) | (49.50M) | (57.42M) | (16.18M) |
| EPS | -3.51 | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Free Cash Flow | (367.84M) | (129.19M) | (81.10M) | (76.84M) | (46.37M) | (25.60M) | (12.51M) |
| FCF / Share | -3.51 | -1.82 | -2.33 | -3.82 | -2.88 | -2.41 | -2.73 |
| Operating CF | (367.82M) | (129.19M) | (81.09M) | (76.78M) | (46.24M) | (25.46M) | (12.47M) |
| Total Assets | 478.69M | 596.27M | 196.82M | 162.42M | 211.07M | 95.55M | 11.37M |
| Total Debt | 37.55M | 27.11M | 20.55M | 19.40M | 0 | 0 | 24.74M |
| Cash & Equiv | 126.06M | 316.16M | 55.26M | 52.43M | 98.18M | 93.36M | 11.23M |
| Book Value | 400.79M | 536.31M | 151.83M | 125.96M | 202.96M | 89.94M | (16.06M) |
| Return on Equity | -0.92 | -0.27 | -0.67 | -0.72 | -0.24 | -0.64 | N/A |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 21,000 | 0 | 0 | 0 | 234,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.50M) | (71.28M) | (118.35M) | (149.07M) | (47.97M) | (51.68M) | (40.23M) | (34.73M) | (38.39M) | (84.12M) | (24.60M) | (26.80M) |
| EPS | -0.71 | -0.49 | -1.02 | -1.39 | -0.48 | -0.54 | -0.50 | -0.45 | -0.52 | -1.58 | -0.48 | -0.57 |
| Free Cash Flow | (100.42M) | (71.81M) | (121.59M) | (145.36M) | (61.16M) | (39.72M) | (34.30M) | (30.36M) | (34.45M) | (30.09M) | (27.10M) | (14.81M) |
| FCF / Share | -0.64 | -0.62 | -1.05 | -1.36 | -0.61 | -0.41 | -0.43 | -0.40 | -0.46 | -0.57 | -0.53 | -0.31 |
| Operating CF | (100.42M) | (71.74M) | (121.58M) | (145.36M) | (61.16M) | (39.72M) | (34.29M) | (30.36M) | (34.45M) | (30.09M) | (27.10M) | (14.81M) |
| Total Assets | 603.49M | 685.03M | 478.69M | 458.30M | 582.14M | 577.32M | 596.27M | 460.11M | 492.51M | 494.32M | 196.82M | 200.58M |
| Total Debt | 37.62M | 37.58M | 37.55M | 37.57M | 27.35M | 27.30M | 27.11M | 24.87M | 24.75M | 24.64M | 20.55M | 20.19M |
| Cash & Equiv | 129.08M | 315.40M | 126.06M | 91.41M | 212.22M | 217.57M | 316.16M | 251.93M | 245.44M | 350.93M | 55.26M | 72.40M |
| Book Value | 521.73M | 605.46M | 400.79M | 378.10M | 514.92M | 510.54M | 536.31M | 410.21M | 441.99M | 445.83M | 151.83M | 152.57M |
| Return on Equity | -0.21 | -0.12 | -0.30 | -0.39 | -0.09 | -0.10 | -0.08 | -0.08 | -0.09 | -0.19 | -0.16 | -0.18 |
ETNB News
No news available for ETNB.